

# Aishat Afuye

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5148726/publications.pdf>

Version: 2024-02-01

7  
papers

479  
citations

1478505

6  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

578  
citing authors

#	ARTICLE	IF	CITATIONS
1	Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 79.	6.2	137
2	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2022, 28, 713-723.	30.7	117
3	DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 3024-3033.	5.2	75
4	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	5.2	64
5	Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.	1.6	60
6	A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. <i>Blood</i> , 2021, 138, 96-96.	1.4	24
7	The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies. <i>Blood</i> , 2021, 138, 253-253.	1.4	2